Charles Cherington - 08 Dec 2021 Form 4 Insider Report for Brooklyn ImmunoTherapeutics, Inc. (ERNA)

Role
Director
Signature
/s/ Mark L. Johnson, Attorney-in-Fact for Charles Cherington
Issuer symbol
ERNA
Transactions as of
08 Dec 2021
Net transactions value
$0
Form type
4
Filing time
10 Dec 2021, 20:00:52 UTC
Previous filing
23 Nov 2021
Next filing
14 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ERNA Common Stock Other $0 +92 +0% $0.000000 5,894,193 01 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ERNA Stock Option Award $0 +67,000 $0.000000 67,000 08 Dec 2021 Common Stock 67,000 $5.94 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a stock dividend declared on shares of the Issuer's Series A Preferred Stock.
F2 A total of 22,336 of the shares subject to the option vest and become exercisable as of 12:01 a.m. Eastern time on the date of the issuer's 2022 Annual Meeting of Stockholders and the remaining 44,664 shares vest and become exercisable in equal monthly installments over the following 24 months, subject to continued service through each vesting date.